financetom
Business
financetom
/
Business
/
Simpple Regains Compliance With Nasdaq's Minimum Bid Price Rule
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Simpple Regains Compliance With Nasdaq's Minimum Bid Price Rule
May 26, 2025 12:24 AM

11:31 AM EDT, 05/02/2025 (MT Newswires) -- Simpple ( SPPL ) said Friday it has regained compliance with Nasdaq's minimum bid price requirement.

The company said it received a notice from the exchange on April 28 confirming that its stock met the required minimum bid price of $1.00 per share, as outlined in the Nasdaq Listing Rule.

From April 7 to April 25, the stock traded at or above $1.00 for 14 consecutive business days, bringing the company back into compliance with Nasdaq's listing standards, it added.

Shares of Simpple ( SPPL ) were nearly 4.7% down in recent trading activity.

Price: 3.67, Change: -0.18, Percent Change: -4.68

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Peraso Receives $3.6 Million Order for mmWave Devices
Peraso Receives $3.6 Million Order for mmWave Devices
Mar 17, 2025
07:35 AM EDT, 03/17/2025 (MT Newswires) -- Peraso ( PRSO ) said Monday it received a $3.6 million purchase order for its mmWave devices from an undisclosed provider of networking systems used for fixed wireless access. The company said it expects to begin shipments in the second quarter, with the remainder to be fulfilled throughout the rest of the year....
Avidity Biosciences Reports Positive Topline Data From Phase 1/2 Trial of Del-Zota to Treat DMD
Avidity Biosciences Reports Positive Topline Data From Phase 1/2 Trial of Del-Zota to Treat DMD
Mar 17, 2025
07:35 AM EDT, 03/17/2025 (MT Newswires) -- Avidity Biosciences ( RNA ) said Monday that topline data from the phase 1/2 EXPLORE44 trial of del-zota to treat Duchenne muscular dystrophy showed consistent, statistically significant improvements in dystrophin, exon skipping and creatine kinase. The biopharmaceutical company said del-zota also demonstrated favorable safety and tolerability in the dose cohorts. It also said...
Sprott Asset Management Seeks to List Sprott Physical Copper Trust Units on NYSE Arca
Sprott Asset Management Seeks to List Sprott Physical Copper Trust Units on NYSE Arca
Mar 17, 2025
07:35 AM EDT, 03/17/2025 (MT Newswires) -- Sprott's Sprott Asset Management subsidiary said Monday that NYSE Arca has filed an application with the US Securities and Exchange Commission to list and trade Sprott Physical Copper Trust units on NYSE Arca. The company said the move would enable dual listing on both the TSX and NYSE Arca, offering broader access to...
Perspective Therapeutics Starts Dosing New Cohort for Melanoma Tumor Treatment Therapy
Perspective Therapeutics Starts Dosing New Cohort for Melanoma Tumor Treatment Therapy
Mar 17, 2025
07:36 AM EDT, 03/17/2025 (MT Newswires) -- Perspective Therapeutics ( CATX ) said Monday the first patient was dosed in a new cohort of its phase 1/2a trial evaluating the safety of targeted alpha-particle therapy [212Pb]VMT01 in patients with histologically confirmed melanoma and positive melanocortin 1 receptor imaging scans. Patients in the new cohort are receiving the therapy in combination...
Copyright 2023-2026 - www.financetom.com All Rights Reserved